Volume 385, Issue 9962, Pages (January 2015)

Slides:



Advertisements
Similar presentations
Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review  David.
Advertisements

Volume 14, Issue 12, Pages (November 2013)
Volume 14, Issue 4, Pages (April 2013)
Volume 385, Issue 9980, Pages (May 2015)
Su K. Metcalfe, MD, MPH, Michael T
Volume 370, Issue 9605, Pages (December 2007)
Volume 12, Issue 11, Pages (October 2011)
Volume 376, Issue 9747, Pages (October 2010)
Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Volume 378, Issue 9809, Pages (December 2011)
Volume 5, Issue 4, Pages (April 2006)
Volume 14, Issue 4, Pages (April 2013)
Volume 377, Issue 9783, Pages (June 2011)
Volume 13, Issue 12, Pages (December 2012)
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Volume 15, Issue 8, Pages (July 2014)
Volume 15, Issue 4, Pages (April 2014)
Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with “Ultracentral” Non–Small Cell Lung Cancer  Hilâl Tekatli, MD, Niels Haasbeek,
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Volume 15, Issue 4, Pages (April 2014)
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial 
Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J
Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.
Adjuvant chemotherapy for rectal cancer – Authors' reply
Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer
Volume 15, Issue 4, Pages (April 2014)
Volume 12, Issue 7, Pages (July 2011)
Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm  Hilâl Tekatli, MD, Saar van ’t Hof, MD, Esther.
Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer  Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,
Chris Dickhoff, MD, Max Dahele, MD, PhD, Sayed M
Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R
Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430  Thomas E.
Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial  Marianna Christodoulou,
Volume 13, Issue 12, Pages (December 2012)
Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327)  Primo N. Lara,
An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.
Volume 20, Issue 1, Pages (January 2019)
Volume 14, Issue 11, Pages (October 2013)
Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer  Masahiko Harada,
Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small- Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of.
Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance) 
Volume 371, Issue 9627, Pages (May 2008)
Volume 18, Issue 8, Pages (August 2017)
Volume 388, Issue 10055, Pages (October 2016)
A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596):
Incidence and Risk Factors for Chest Wall Toxicity After Risk-Adapted Stereotactic Radiotherapy for Early-Stage Lung Cancer  Eva M. Bongers, MD, Cornelis.
Volume 373, Issue 9658, Pages (January 2009)
Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy  Naomi E. Verstegen,
Volume 378, Issue 9809, Pages (December 2011)
Volume 373, Issue 9658, Pages (January 2009)
Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)  Gregory A. Otterson,
ACST: which subgroups will benefit most from carotid endarterectomy?
Volume 11, Issue 1, Pages (January 2010)
Volume 376, Issue 9747, Pages (October 2010)
Volume 14, Issue 9, Pages (August 2013)
Recurrence after low-dose radioiodine ablation and recombinant human thyroid- stimulating hormone for differentiated thyroid cancer (HiLo): long-term results.
Interferon alfa-2a for melanoma metastases
Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J
A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104  Ramaswamy Govindan, MD, Xiaofei.
Volume 14, Issue 7, Pages (June 2013)
Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.
Journal of Thoracic Oncology
A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell.
Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer  James B. Yu, MD, Roy H. Decker, MD, PhD,
A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.
Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339) 
Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients  Barbara S. van der Meij,
Presentation transcript:

Volume 385, Issue 9962, Pages 36-42 (January 2015) Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial  Ben J Slotman, MD, Harm van Tinteren, PhD, John O Praag, MD, Joost L Knegjens, MD, Sherif Y El Sharouni, MD, Matthew Hatton, FRCR, Astrid Keijser, MSc, Corinne Faivre-Finn, PhD, Suresh Senan, FRCR  The Lancet  Volume 385, Issue 9962, Pages 36-42 (January 2015) DOI: 10.1016/S0140-6736(14)61085-0 Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile The Lancet 2015 385, 36-42DOI: (10.1016/S0140-6736(14)61085-0) Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 2 Kaplan-Meier curves for overall survival The Lancet 2015 385, 36-42DOI: (10.1016/S0140-6736(14)61085-0) Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 3 Overall survival at 1 year in subgroups *CI is 99% for subgroups, 95% for total. CR=complete response. PR=partial response. The Lancet 2015 385, 36-42DOI: (10.1016/S0140-6736(14)61085-0) Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 4 Kaplan-Meier curves for progression-free survival The Lancet 2015 385, 36-42DOI: (10.1016/S0140-6736(14)61085-0) Copyright © 2015 Elsevier Ltd Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.